申请人:Taisho Pharmaceutical Co. Ltd.
公开号:EP2177526A1
公开(公告)日:2010-04-21
A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
一种在 10a- 位和 12- 位交联的新型 10a- 叠氮酰胺化合物,由下式表示,甚至对流感嗜血杆菌或红霉素耐药菌(如耐药肺炎球菌和链球菌)也有效。